Bull or Bear
This content is for members
This content is for members
This content is for members
Exelixis (EXEL) completed the submission of a supplemental New Drug Application (sNDA) to the FDA for Cabometyx® (cabozantinib) tablets for previously treated …
Juno Therapeutics’ (JUNO) stock price orbited the moon after-hours trading yesterday, rising 45%, following a wall street journal report stating that Celgene …
As part of its ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially available compounds, cabozantinib and …
This content is for members
This content is for members
This content is for members
This content is for members
This content is for members
Two game changing news has come together on October 16, 2017, both indicating that Exelixis (EXEL) is on its way to reach its goal becoming the leader in the …
Exelixis (EXEL) announced that Daiichi Sankyo (“Daiichi Sankyo”) reported positive top-line results from a phase 3 pivotal trial of esaxerenone for …
This content is for members
This content is for members
This content is for members
This content is for members